Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Cellectis S.A.NASDAQ: CLLS

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q1 FY2026 revenue of $5.8M fell 45.6% year over year, behind the +42.9% change in trailing-twelve-month revenue. Sequentially, it fell 44.2% from the prior quarter. Over 3 fiscal years it compounded at +56.1% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $40.11M (-45.0%) for the fiscal year ending Dec 2026, a slowdown from the +75.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.8M-44.2% QoQ
Last fiscal yearDec 2025
$72.95M+75.8% YoY
LTMMar 2026
$68.09M+42.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.6%-33.9%+11.7 pp
1 year+75.8%-45.0%-120.8 pp
3-year CAGR+56.1%-2.4%-58.5 pp
5-year CAGR-19.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
72.95M USD
Year-over-year change
+75.8%
4-year CAGR
+24.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +42.9% is the highest of 5, against a peer median of -53.6%.
  • Over three fiscal years its annual growth of +56.1% compares with a peer median of -16.7%.
CLLS Competitors
Revenue for CLLS and competitors
Company Period LTM YoY 3-year CAGR
AMRNAmarin Corporation plcLTM Mar 2026$214.88M USD+0.3%-16.7%
CLLSCellectis S.A.LTM Mar 2026$68.09M USD+42.9%+56.1%
KRROKorro Bio, Inc.LTM Mar 2026$3.84M USD-20.3%—
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%
SLNSilence Therapeutics plcLTM Mar 2026$921.49K USD—-68.4%
MREOMereo BioPharma Group plcLTM Mar 2026$500K USD——
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD——
ANROAlto Neuroscience, Inc.LTM Mar 2026$0 USD——
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD——
DBVTDBV Technologies S.A.LTM Mar 2026$0 USD-100.0%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD——
Peer median (excluding CLLS) —-53.6%-16.7%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.